https://ir.evommune.com/ https://ir.evommune.com/company-info https://ir.evommune.com/company-info/presentations https://ir.evommune.com/company-info/contacts https://ir.evommune.com/company-info/faq https://ir.evommune.com/news-events/press-releases https://ir.evommune.com/news-events/ir-calendar https://ir.evommune.com/news-events/email-alerts https://ir.evommune.com/stock-data/quote-chart https://ir.evommune.com/stock-data/historical-data https://ir.evommune.com/stock-data/analyst-coverage https://ir.evommune.com/financial-information/financial-results https://ir.evommune.com/financial-information/sec-filings https://ir.evommune.com/governance https://ir.evommune.com/governance/board-committees https://ir.evommune.com/governance/governance-documents https://ir.evommune.com/news-events/press-releases/detail/121/evommune-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-highlights 2026-03-05T16:01:01-05:00 https://ir.evommune.com/news-events/press-releases/detail/120/evommune-announces-125-million-private-placement 2026-02-12T20:30:01-05:00 https://ir.evommune.com/news-events/press-releases/detail/119/evommune-announces-positive-top-line-data-from-phase-2a-proof-of-concept-trial-of-evo301-in-moderate-to-severe-atopic-dermatitis 2026-02-10T07:30:02-05:00 https://ir.evommune.com/news-events/press-releases/detail/118/evommune-reports-third-quarter-2025-financial-results-and-provides-business-update 2025-12-11T16:05:05-05:00 https://ir.evommune.com/news-events/press-releases/detail/117/evommune-announces-closing-of-its-initial-public-offering-and-full-exercise-of-underwriters-option-to-purchase-additional-shares 2025-11-07T16:05:02-05:00 https://ir.evommune.com/news-events/press-releases/detail/116/evommune-announces-pricing-of-its-initial-public-offering 2025-11-05T19:45:37-05:00 https://ir.evommune.com/news-events/press-releases/detail/115/evommune-announces-commencement-of-initial-public-offering 2025-11-05T09:08:05-05:00 https://ir.evommune.com/news-events/press-releases/detail/85/evommune-presents-full-phase-2-data-for-oral-mrgprx2-inhibitor-evo756-in-chronic-inducible-urticaria-during-late-breaker-at-eadv-2025-congress 2025-11-05T09:08:05-05:00 https://ir.evommune.com/news-events/press-releases/detail/86/evommune-announces-late-breaker-presentation-of-phase-2-data-for-evo756-in-chronic-inducible-urticaria-at-upcoming-european-academy-of-dermatology-and-venereology-eadv-2025-congress 2025-11-05T09:08:06-05:00 https://ir.evommune.com/news-events/press-releases/detail/87/evommune-to-participate-in-three-upcoming-investor-conferences 2025-11-05T09:08:06-05:00 https://ir.evommune.com/news-events/press-releases/detail/88/evommune-initiates-phase-2b-trial-of-its-oral-mrgprx2-antagonist-evo756-in-adults-with-moderate-to-severe-atopic-dermatitis 2025-11-05T09:08:06-05:00 https://ir.evommune.com/news-events/press-releases/detail/89/evommune-announces-top-line-data-from-phase-2-trial-of-evo756-in-chronic-inducible-urticaria-demonstrating-robust-activity-and-favorable-safety-profile 2025-11-05T09:08:06-05:00 https://ir.evommune.com/news-events/press-releases/detail/90/evommune-initiates-phase-2b-trial-of-mrgprx2-antagonist-evo756-in-adults-with-moderate-to-severe-chronic-spontaneous-urticaria 2025-11-05T09:08:06-05:00 https://ir.evommune.com/news-events/press-releases/detail/91/evommune-initiates-phase-2-trial-of-il-18-targeted-fusion-protein-evo301-in-adult-patients-with-atopic-dermatitis 2025-11-05T09:08:07-05:00 https://ir.evommune.com/news-events/press-releases/detail/92/evommune-presents-positive-clinical-results-of-its-mrgprx2-antagonist-evo756-at-the-7th-galen-global-urticaria-forum 2025-11-05T09:08:07-05:00 https://ir.evommune.com/news-events/press-releases/detail/93/evommune-announces-115-million-series-c-financing-to-accelerate-advancement-of-clinical-stage-pipeline-addressing-chronic-inflammatory-diseases 2025-11-05T09:08:07-05:00 https://ir.evommune.com/news-events/press-releases/detail/94/evommune-initiates-phase-2-trial-of-evo756-an-oral-mrgprx2-antagonist-in-chronic-inducible-urticaria 2025-11-05T09:08:07-05:00 https://ir.evommune.com/news-events/press-releases/detail/95/evommune-announces-positive-proof-of-concept-clinical-trial-results-for-its-mrgprx2-antagonist-evo756 2025-11-05T09:08:07-05:00 https://ir.evommune.com/news-events/press-releases/detail/96/evommune-secures-exclusive-rights-to-develop-and-commercialize-a-phase-2-ready-il-18-targeted-fusion-protein-from-aprilbio 2025-11-05T09:08:07-05:00 https://ir.evommune.com/news-events/press-releases/detail/97/evommune-announces-expanded-strategic-collaboration-with-maruho-to-develop-and-commercialize-mrgprx2-antagonist-evo756-in-greater-china-and-key-asian-countries 2025-11-05T09:08:08-05:00 https://ir.evommune.com/news-events/press-releases/detail/98/evommune-announces-initiation-of-a-phase-1-trial-of-its-mrgprx2-antagonist-for-the-treatment-of-chronic-spontaneous-urticaria 2025-11-05T09:08:08-05:00 https://ir.evommune.com/news-events/press-releases/detail/99/evommune-and-accutar-biotechnology-announce-ai-drug-discovery-collaboration 2025-11-05T09:08:08-05:00 https://ir.evommune.com/news-events/press-releases/detail/100/evommune-announces-strategic-collaboration-with-maruho-to-develop-and-commercialize-mrgprx2-antagonist-evo756-in-japan 2025-11-05T09:08:08-05:00 https://ir.evommune.com/news-events/press-releases/detail/101/evommune-adds-additional-investment-in-series-b-financing-and-bolsters-leadership-team 2025-11-05T09:08:08-05:00 https://ir.evommune.com/news-events/press-releases/detail/102/evommune-closes-50-million-series-b-financing-to-advance-broad-pipeline-of-therapies-to-treat-chronic-inflammatory-diseases 2025-11-05T09:08:08-05:00 https://ir.evommune.com/news-events/press-releases/detail/103/evommune-announces-appointment-of-dr-jeegar-patel-as-chief-scientific-officer 2025-11-05T09:08:08-05:00 https://ir.evommune.com/news-events/press-releases/detail/104/evommune-initiates-phase-2a-proof-of-concept-clinical-trial-to-evaluate-evo101-in-atopic-dermatitis 2025-11-05T09:08:09-05:00 https://ir.evommune.com/news-events/press-releases/detail/105/evommune-announces-appointment-of-greg-moss-as-chief-corporate-strategy-and-legal-officer 2025-11-05T09:08:09-05:00 https://ir.evommune.com/news-events/press-releases/detail/106/evommune-announces-appointment-of-kyle-carver-as-chief-financial-officer 2025-11-05T09:08:09-05:00 https://ir.evommune.com/news-events/press-releases/detail/107/evommune-initiates-phase-1-study-to-evaluate-safety-of-evo101-an-irak4-inhibitor-in-healthy-volunteers 2025-11-05T09:08:09-05:00 https://ir.evommune.com/news-events/press-releases/detail/108/evommune-to-present-at-the-2021-american-college-of-toxicology-annual-meeting-and-the-annual-dermatology-drug-development-summit-for-inflammatory-diseases 2025-11-05T09:08:09-05:00 https://ir.evommune.com/news-events/press-releases/detail/109/evommune-inc-completes-83-million-series-a-financing-to-advance-development-of-unique-chronic-inflammation-pipeline 2025-11-05T09:08:09-05:00 https://ir.evommune.com/news-events/press-releases/detail/110/evommune-to-present-at-the-20th-annual-needham-virtual-healthcare-conference 2025-11-05T09:08:10-05:00 https://ir.evommune.com/news-events/press-releases/detail/111/evommune-in-licenses-three-development-programs-focused-on-treating-inflammatory-conditions-from-dermira-a-wholly-owned-subsidiary-of-eli-lilly-and-company 2025-11-05T09:08:10-05:00 https://ir.evommune.com/news-events/press-releases/detail/112/evommune-to-present-at-2021-virtual-dermatology-summit 2025-11-05T09:08:10-05:00 https://ir.evommune.com/news-events/press-releases/detail/113/evommune-and-axcelead-drug-discovery-partners-launch-a-collaboration-on-a-pkctheta-program-to-kick-off-evommunes-inflammation-pipeline 2025-11-05T09:08:10-05:00 https://ir.evommune.com/news-events/press-releases/detail/114/evommune-inc-raises-12-5m-in-seed-funding-to-accelerate-the-development-of-transformative-medicines-for-chronic-inflammatory-diseases 2025-11-05T09:08:10-05:00 https://ir.evommune.com/news-events/ir-calendar/detail/20260311-leerink-partners-global-healthcare-conference 2026-03-05T16:02:00-05:00 https://ir.evommune.com/news-events/ir-calendar/detail/20260210-evommune-evo301-top-line-results-from-phase-2a-trial-in-moderate-to-severe-atopic-dermatitis 2026-02-10T08:31:15-05:00 https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-093920/evmn-20260305.htm 2026-03-05T16:14:06-05:00 https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-093932/evmn-20251231.htm 2026-03-05T16:17:35-05:00 https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-093978/evmn-20260305.htm 2026-03-05T16:24:23-05:00 https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-059500/ownership.html 2026-02-19T16:30:37-05:00 https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-059504/primary_doc.html 2026-02-19T16:30:40-05:00 https://ir.evommune.com/financial-information/sec-filings/content/0002094941-26-000002/form4-02192026_020236.html 2026-02-18T21:19:59-05:00 https://ir.evommune.com/financial-information/sec-filings/content/0001231919-26-000164/form4-02182026_120251.html 2026-02-17T19:28:41-05:00 https://ir.evommune.com/financial-information/sec-filings/content/0001346824-26-000063/primary_doc.html 2026-02-17T19:29:22-05:00 https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-049888/evmn-20260212.htm 2026-02-13T08:01:12-05:00 https://ir.evommune.com/financial-information/sec-filings/content/0001012975-26-000142/primary_doc.html 2026-02-13T16:11:03-05:00 https://ir.evommune.com/financial-information/sec-filings/content/0001193125-26-043771/evmn-20260210.htm 2026-02-10T08:29:38-05:00 https://ir.evommune.com/financial-information/sec-filings/content/0001012975-25-000937/form4.html 2025-12-22T07:08:12-05:00 https://ir.evommune.com/company-info/presentations/detail/35114/march-2026-corporate-presentation 2026-03-05T00:00:00-05:00 https://ir.evommune.com/privacy-policy https://ir.evommune.com/disclaimer https://ir.evommune.com/sitemap